A medical imaging company that spun out of GE in 2023 just reported Q2 earnings with a 9% EPS beat, posted a record $23.9 billion backlog driven by 11% organic order growth, and initiated a strategic review of its Patient Care Solutions segment that may lead to a sale, while two of its directors recently bought shares personally at prices well below where the stock trades now.
The setup heading forward is whether the PCS review concludes favorably, the back-half revenue recovery materializes, and AI-enabled product launches start showing up in software attach rates.
Standout Picks Now (Sponsored)
Every market cycle produces a handful of companies that dramatically outperform the rest.
Our latest screening has identified the 5 Stocks Set to Double — companies showing rare early-stage momentum traits.
These picks carry the same indicators that historically precede strong rallies.
Past reports highlighted stocks that surged +175%, +498%, and +673%.
Get the Free 5 Stocks Set to Double Report.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
The Q2 Beat Is Behind Us. The Real Story Is What Comes Next
GE HealthCare Technologies Inc. (NASDAQ: GEHC) closed at $72.94, up roughly 10% over the past month following Q2 results that beat expectations on both lines. Revenue of $5.29 billion came in ahead of estimates and grew 5.8% year over year.
Adjusted EPS of $1.13 beat the $1.04 consensus by 9.1%. Organic order growth hit 11.1% year over year, pushing total backlog to a record $23.9 billion, with a book-to-bill of 1.15.
The 52-week range is $58.75 to $89.77, and the stock is currently trading closer to the low end of that range than the high despite the recent move.
The beat is not the interesting part. The interesting part is everything that happened alongside it.
Management initiated a strategic review of the Patient Care Solutions segment, which includes patient monitoring, anesthesia, and respiratory care, and explicitly flagged that a potential sale is on the table.
That segment represents roughly 15% of revenue and has been the drag on the consolidated margin story. If it gets sold, what remains is a cleaner, higher-margin imaging and diagnostics business that would reasonably command a better multiple.
Q2 EPS $1.13, beat by 9.1% against $1.04 consensus: Clean top-and-bottom beat.
Backlog at record $23.9 billion, book-to-bill 1.15: More equipment ordered than shipped, consistently.
Patient Care Solutions under strategic review, potential sale on the table: The drag on margins and roughly 15% of revenue.
Stock at $73, 52-week range $58.75 to $89.77: Well off the high despite the recovery.
At roughly 16.5 times earnings, the market has not priced in a back-half recovery or the potential value from a PCS sale.
Action: Build a position at $72 to $75. Record backlog, strategic review in progress, and director buying at lower prices give you multiple ways to win. Hard stop $63.
Elite Picks (Sponsored)
This report focuses on a narrow group of stocks identified through a detailed screening process.
Analysts apply a combination of metrics to narrow down potential opportunities.
Past selections have shown strong momentum, but no outcomes are guaranteed.
The newest edition is now open for access.
Get the report now.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
The Record Backlog Is the Leading Indicator That Matters Most
Medical imaging equipment is a long-cycle capital purchase. Hospitals do not order MRI systems, CT scanners, and ultrasound platforms impulsively.
When the backlog grows to a record and book-to-bill exceeds 1.1, it means the orders sitting in the pipeline will convert to revenue over the coming quarters. That is not a soft signal. It is a hard constraint on future revenue direction.
Hospital capital spending froze during the rate-hike cycle. Equipment purchases got deferred, not cancelled.
Rates are moving lower, and hospital margins are recovering. Hospitals did not stop needing MRI machines. They just stopped ordering them for a while.
The installed base makes this structural. Four-plus million imaging devices generate recurring service and software revenue independently of new equipment orders.
AI-enabled upgrades on existing hardware generate high-margin revenue without a new unit sale.
11% organic order growth in Q2: Deferred hospital capex is coming back through the pipeline.
Over four million imaging devices in global installed base: Software and service attach rates compound on this base.
New AI-enabled ultrasound and breast imaging platforms launched: Higher-margin software workflows on existing hardware.
Action: On the next call, watch book-to-bill vs 1.1 and backlog vs $24 billion. Two consecutive quarters above 1.1 confirms the recovery is structural.
Warning signs (Sponsored)
The headlines keep getting bigger.
New IPOs, soaring valuations, and speculative bets are dominating the market conversation.
But one longtime Wall Street veteran believes investors may be overlooking growing risks beneath the surface.
In a new free briefing, he explains what concerns him most—and the steps he's taking to prepare.
Watch the Free Analysis
The Patient Care Solutions Review Is the Margin Catalyst Nobody Priced In
Patient Care Solutions declined 13.5% in organic revenue last quarter. That is not a segment in recovery. That is a segment with manufacturing and operational challenges that management has been navigating for over a year.
The decision to initiate a formal strategic review, including a potential sale, is management finally acknowledging what the numbers have been saying.
If PCS is sold, what remains is imaging, ultrasound, pharmaceutical diagnostics, and AI-enabled software. All carry better margins and growth trajectories than PCS.
Removing a 13.5% declining segment immediately improves reported growth rates and allows the margin profile to step up.
A sale at a reasonable multiple is the best outcome. A restructuring that improves PCS economics is second-best. Status quo would disappoint.
Patient Care Solutions' organic revenue declined 13.5% last quarter: Not healing. Actively declining.
Strategic review initiated including potential sale: Management took the formal step.
PCS is roughly 15% of revenue: Big enough to matter, small enough the core survives without it.
A sale would meaningfully improve reported growth and margin profile: The remaining business is a cleaner story.
Action: Watch for PCS review news. A sale at a reasonable valuation is a buy-more signal. No sale means reassessing the timeline for organic margin improvement.
While the stock was sitting near the lower end of its 52-week range, two separate directors made open-market purchases. One director acquired 1,618 shares at approximately $62 per share.
A second director acquired 10,000 shares at approximately $64 per share. Together, that is meaningful personal capital deployed at prices roughly 13% to 15% below where the stock trades now.
Directors buying in the open market have access to everything the board sees. They decided to write personal checks at those prices anyway. The 10,000-share purchase is not a token amount.
Those directors are sitting on gains. That does not make the thesis less valid. It makes the floor more visible.
Director acquired 1,618 shares at approximately $62: An open-market purchase at the lower end of the range.
Second director acquired 10,000 shares at approximately $64: A much larger commitment and a strong signal.
Both purchases came at the lower end of the 52-week range: Buying into weakness, not chasing strength.
Action: After the next quarterly print, check Form 4 filings. Either a director adding to their position signals continued inside confidence.
The Honest Complications: CFO Departure, Macro Headwind, and a Hold Consensus
The CFO announced his departure to join an external firm. The company is now running an interim leadership search alongside managing the back-half execution requirements.
CFO transitions at companies managing complex strategic reviews and fiscal year-end execution are not ideal timing. It adds uncertainty and management attention risk that should factor into position sizing.
The full-year macro headwind stands at $250 million from freight, oil, and component costs. That is a real number, not a rounding error.
It constrains the flow-through benefit of top-line revenue growth and is why margin expansion has been gradual despite the order book strength. China exposure at roughly 13% of revenue is also a tariff risk surface that management monitors closely.
Analyst consensus is Hold, not Buy, with an average target around $77.73. Limited near-term upside to consensus without a catalyst.
The bull case requires a PCS sale or continued back-half beats that push estimates higher.
CFO departing, interim leadership transition underway: Not ideal timing against a strategic review and back-half execution.
$250 million full-year macro headwind from freight and components: Constrains margin flow-through from top-line growth.
Analyst consensus currently Hold, average target around $77.73: Limited upside to consensus without a catalyst.
China represents roughly 13% of revenue with tariff exposure: A real variable that moves the margin needle.
Action: Hard stop $63. Q3 miss plus disappointing PCS update plus no CFO replacement named means exit at $63.
Trivia: The term "blue chip" is standard market vocabulary — but where does it actually come from?
- It was coined by London brokers in 1875, borrowed from the card game whist
- A Dow Jones journalist named Oliver Gingold applied the poker term to high-quality stocks in the 1920s
- It originated in a 1942 Wall Street Journal article about the newly expanded Dow 30
- Benjamin Graham introduced it in the first edition of Security Analysis
The Product Pipeline Is Adding a Software Layer Nobody Has Fully Modeled
The new AI-enabled portable ultrasound systems represent exactly the kind of product that changes the economics of the installed base argument.
Portable ultrasound that operates at near-console quality, with AI-driven workflow tools built in, extends the imaging footprint into outpatient clinics, rural hospitals, and point-of-care settings that previously lacked that capability.
Every new device placed is a new entry point for software subscription revenue.
The breast imaging expansion with the Invenia ABUS Prime and ABUS StreamVue platforms addresses a specific and growing clinical need in dense-breast screening.
The standardization of that workflow creates recurring protocol revenue and positions the company for expanded clinical use guidelines, which tend to create sustained multi-year pull when they update.
Theranostics ties diagnostic imaging to targeted cancer treatment and grows at double-digit rates annually.
The existing installed base is a natural distribution channel. The current multiple looks anchored to the old business model, not where the revenue mix is heading.
AI-enabled portable ultrasound extending into outpatient and point-of-care: Each new placement creates a software subscription revenue entry point.
Dense-breast imaging platforms standardizing screening workflows: Recurring protocol revenue with multi-year clinical adoption tailwinds.
Theranostics positioning in targeted cancer treatment: Longer-horizon optionality that is not yet in the consensus model.
Action: On the next call, listen for software attach rate data across the imaging portfolio. That metric drives the margin expansion story.
Final Word: A Cleaner Business Is Taking Shape If You Give It Time
Record backlog. A 9% Q2 EPS beat. A strategic review aimed at removing the worst-performing segment and leaving a cleaner margin profile. Two directors who bought shares at meaningful prices.
AI product launches that add software revenue on top of a four-million-device installed base. A CFO transition and a $250 million macro headwind are the complications.
The consensus is Hold and the average target is close to current prices. The case for owning it is that PCS sale and continued back-half execution would change what analysts model.
Buy at $72 to $75. Hard stop $63. Target $87 to $90.
Setup Scorecard
Entry Window: $72 to $75. The stock is well off the $89.77 high with a cleaner business taking shape through the PCS review.
Catalyst Watch: Patient Care Solutions strategic review resolution, Q3 results for back-half revenue acceleration, CFO successor announcement, software attach rate data, backlog trend vs $23.9 billion record.
Upside Setup: PCS sold at a reasonable valuation, back-half revenue accelerates in line with the record backlog, AI-enabled software attach rates start showing up in margins. Target $87 to $90 over 9 to 12 months.
Downside Cushion: Record $23.9 billion backlog provides multi-quarter revenue visibility, director buying at $62 to $64 defines a visible floor, full-year EPS guidance held at $4.80 to $5.00 despite Q2 headwinds, 16.5x P/E with a cleaner business taking shape.
What Moves It Next: PCS strategic review outcome, Q3 order growth vs 11.1% Q2 baseline, CFO replacement named, software revenue data, and whether the $250 million macro headwind shows any relief.
That's our coverage for today; thanks for reading! Reply to this email with feedback or any [blank] stocks you want me to check out.
Best Regards,
—Noah Zelvis
Undervalued Edge
